Therapeutic options for cutaneous lupus erythematosus: recent advances and future prospects

Chang, Joshua; Werth, Victoria P.

doi:10.1080/1744666x.2016.1188006

Cited by 16 publications

(14 citation statements)

References 127 publications

(129 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite their similarities in efficacy, 35 HCQ is generally the first systemic agent to be prescribed, in part because of the greater risk of toxic retinopathy with CQ. 36 A recent double-blinded randomized controlled parallel-group trial showed greater improvements in the investigator's global assessment in the HCQ group compared to placebo (51.4% versus 8.7%). 37 In those patients who fail to improve with HCQ alone, the addition of quinacrine increases the likelihood of response.…”

Section: Systemic Therapiesmentioning

confidence: 99%

A review of the evidence and cost of therapies for cutaneous lupus erythematosus

Rosen

Paul

2019

Lupus

View full text Add to dashboard Cite

Cutaneous lupus erythematosus (CLE)—a common presentation of lupus erythematosus—may exist independently or as a part of the systemic manifestations of systemic lupus erythematosus. The effects of living with and treating a chronic condition such as CLE can be debilitating to a patient's health and finances. The management of patients with CLE is made particularly challenging by poor compliance, limited therapeutic options, scarcity of evidence supporting their use, and significant differences in costs of medications. Effective management of CLE should center on prevention, individualized treatment regimens, and a mutual understanding of the challenges that patients with CLE face. This article seeks to provide an overview of the efficacy, safety, and cost of therapeutic options for CLE.

show abstract

Section: Systemic Therapiesmentioning

confidence: 99%

A review of the evidence and cost of therapies for cutaneous lupus erythematosus

Rosen

Paul

2019

Lupus

View full text Add to dashboard Cite

show abstract

“…105 HCQ is superior to CQ with its greater risk of toxic retinopathy. 106 HCQ is the preferred agent because of its efficacy and tolerability. 4,107 Considering the safety, HCQ can be also prescribed to pregnant women.…”

Section: Established Therapiesmentioning

confidence: 99%

The pathogenesis of cutaneous lupus erythematosus: The aberrant distribution and function of different cell types in skin lesions

Zhou

Yan

et al. 2020

Scand J Immunol

View full text Add to dashboard Cite

Lupus erythematosus (LE) is an autoimmune disease with diverse and complicated aetiology, including systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). CLE is a common manifestation of SLE, resulting in disfiguring scars, permanent hair loss and significant loss of quality of life for patients. 1 According to Gilliam and Sontheimer, CLE can be subdivided into three categories: acute cutaneous lupus erythematosus (ACLE), subacute cutaneous lupus erythematosus (SCLE) and chronic cutaneous lupus erythematosus (CCLE). 2 ACLE is often associated with systemic symptoms. 3 Half of SCLE patients meet criteria for SLE, though both of ACLE and SCLE often have mild SLE symptoms. 2 CCLE includes five different forms: discoid LE (DLE), verrucous/hypertrophic LE, LE profundus/panniculitis (LEP), LE tumidus (LET) and chilblain LE (CHLE). 3 DLE is the most

show abstract

“…Intralesional steroid injections can be used for localized disease, particularly the DLE subtype (Chang and Werth, 2016). Intramuscular corticosteroid injections can also be used.…”

Section: Treatment Optionsmentioning

confidence: 99%

Cutaneous lupus erythematosus: A review of the literature

Blake

Daniel

2019

International Journal of Women's Dermatology

View full text Add to dashboard Cite

Knowledge with regard to the pathogenesis of lupus erythematosus has progressed rapidly over the past decade, and with it has come promising new agents for the treatment of cutaneous lupus erythematous (CLE). Classification of CLE is performed using clinical features and histopathologic findings, and is crucial for determining prognosis and choosing therapeutic options. Preventative therapy is critical in achieving optimal disease control, and patients should be counseled on sun-safe behavior and smoking cessation. First-line therapy includes topical corticosteroids and calcineurin inhibitors, with antimalarial therapy. Traditionally, refractory disease was treated with oral retinoids, dapsone, and other oral immunosuppressive drugs, but new therapies are emerging with improved side effect profiles and efficacy. Biologic agents, such as belimumab and ustekinumab, have been promising in case studies but will require larger trials to establish their role in routine therapy. Other novel therapies that have been trialed successfully include spleen tyrosine kinase inhibitors and fumaric acid esters. Finally, new evidence has been published recently that describes safer dosing regimens in thalidomide and lenalidomide, both effective medications for CLE. Given the chronic disease course of CLE, long-term treatment-related side effects must be minimized, and the introduction of new steroid-sparing agents is encouraging in this regard.

show abstract

Therapeutic options for cutaneous lupus erythematosus: recent advances and future prospects

Cited by 16 publications

References 127 publications

A review of the evidence and cost of therapies for cutaneous lupus erythematosus

A review of the evidence and cost of therapies for cutaneous lupus erythematosus

The pathogenesis of cutaneous lupus erythematosus: The aberrant distribution and function of different cell types in skin lesions

Cutaneous lupus erythematosus: A review of the literature

Contact Info

Product

Resources

About